Skip to content
Search

Latest Stories

The Pharmacy Show - Buying and Selling Pharmacies

The Pharmacy Show - Buying and Selling Pharmacies

Thorrun Govind and Chris Peace from Brabners shared tips on buying your first pharmacy or building your portfolio at the recent Pharmacy Show 

The Pharmacy Show is a pivotal event for the key players in the pharmacy industry. It’s also an opportunity to gain fresh insights as you embark on your next healthcare venture. TV Pharmacist and Healthcare lawyer (Brabners) Thorrun Govind took to the stage for a packed session at The Pharmacy Show 2024 to share some legal hints and tips. She was joined by her Brabners legal colleague Chris Peace. We share some of the insights from their talk on buying your first pharmacy or building your portfolio here:

Market Overview

Govind explained that the UK pharmacy sales market in 2023 had an unprecedented initial six months owing to the decision taken by parent company Hallo Healthcare Group to divest their portfolio of over 1,054 Lloyds Pharmacies. The divestment created a fever-pitch level of demand from potential buyers both within the market and outside. Since then, other multiples such as Boots have opted to divest some branches, although on a significantly smaller scale than Lloyds.


Govind noted the uncertainty surrounding the upcoming Autumn Budget. Whilst Peace noted the expectation that the government will make significant changes to Capital Gains Tax (CGT) rules. Should (as many anticipate) the government bring in a transitional period for the implementation of any tax changes, we may also expect a heightened ‘fire sale’ flurry of activity in the upcoming months.

The Pharmacy Show Chris Peace (2nd from left) and Thorrun Govind (3rd from left) at The Pharmacy Show

Buying a Pharmacy

Govind sympathised that buying a pharmacy can be daunting, especially for first-time buyers:

  1. Finding a Business:
    • Independently: You may hear of pharmacies for sale in your local area or through your network. Working or locuming at a pharmacy where the owner is looking to sell can be advantageous. If the business has not been widely advertised to the market, then you may face less competition and through your existing association with the seller possibly secure a better price. However, Govind explained that on the downside, if you are an inexperienced buyer, you may end up paying over the odds if you do not have a good understanding of valuation methodologies.
    • Through a Broker: Register as an interested buyer with pharmacy brokers. They can help you find a pharmacy for sale and often, the seller pays the broker fees.
  2. Financing Your Purchase:
    • Determine how much you can realistically borrow and compare interest rates. Specialist financial institutions understand the pharmacy sector and are prepared to lend against pharmacy goodwill valuations.
    • Govind highlighted that having an ‘offer in principle’ from a bank can build confidence with the seller and speed up the acquisition process.
  3. Professional Advisors:
    • Brabners lawyers Chris Peace and David Seddon, have supported over 1,500 transactions between them and specialise in this field.  This was evident by the experienced response to the numerous questions fielded by the audience.
    • Govind explained that an accountant or tax advisor with experience in the retail pharmacy sector is also vital. Specialist pharmacy solicitors and accountants can be invaluable, not just in guiding you through the transaction process but also in supporting you through the early stages of the business when you are most likely to need sound advice.
  4. Due Diligence:
    • Peace highlighted the importance of assessing the health of the business by asking the right questions. He explained that an experienced pharmacy lawyer can help you with this and ensure matters run more efficiently.  Enquiries should cover all aspects of the target business, including local doctors’ surgeries, nursing homes, and pending NHS contract applications. Govind advised that the last three years’ annual accounts and FP34s should also be obtained, to accurately quantify historic prescription sales, as well as current management accounts, which will reveal any recent business deterioration.

Despite the challenging financial outlook, there was plenty of interest from young, entrepreneurial pharmacists in the audience eager to own their pharmacies.  We also hope to see many of these new owners entering the next Pharmacy Business Awards 2025.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less